0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2019
Published Date: March 2019
|
Report Code: DELV-Pipe-048
Home | Market Reports | Health | Pharmacy
Primary Progressive Multiple Sclerosis Pipeline Insight 2019

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2019

Code: DELV-Pipe-048
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

"Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2019” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Primary Progressive Multiple Sclerosis (PPMS) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Primary Progressive Multiple Sclerosis (PPMS)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Primary Progressive Multiple Sclerosis (PPMS)
The report assesses the active Primary Progressive Multiple Sclerosis (PPMS) pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Primary Progressive Multiple Sclerosis (PPMS)
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Primary Progressive Multiple Sclerosis (PPMS)
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Primary Progressive Multiple Sclerosis (PPMS)
• The report also covers the dormant and discontinued pipeline projects related to the Primary Progressive Multiple Sclerosis (PPMS)

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Primary Progressive Multiple Sclerosis (PPMS) to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Primary Progressive Multiple Sclerosis (PPMS) therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

1. Report Introduction
2. Primary Progressive Multiple Sclerosis (PPMS) Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS)
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

LIST OF TABLES :

Table 1: Total Products for Primary Progressive Multiple Sclerosis (PPMS)
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products

LIST OF FIGURES :

Figure 1: Total Products for Primary Progressive Multiple Sclerosis (PPMS)
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$1250
This license allows only one user to access the PDF.

Electronic (PDF)
$2500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$4000
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Seventh Sense AI

RELATED REPORTS

Global and Japan Mycoplasma Pneumoniae Antibodies Market Insights Forecast to 2027
Global and Japan Mycoplasma Pneumoniae Antibodies Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-29Q7590
Wed Nov 24 00:00:00 UTC 2021

Add to Cart

Global and China Trial Size Antibodies Market Insights Forecast to 2027
Global and China Trial Size Antibodies Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-16R7748
Wed Nov 24 00:00:00 UTC 2021

Add to Cart

Global and China Streptococcus Agalactiae Antibodies Market Insights Forecast to 2027
Global and China Streptococcus Agalactiae Antibodies Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-32O7651
Wed Nov 24 00:00:00 UTC 2021

Add to Cart

Global and Japan Streptococcus Group B Antibodies Market Insights Forecast to 2027
Global and Japan Streptococcus Group B Antibodies Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-33W7483
Wed Nov 24 00:00:00 UTC 2021

Add to Cart